Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development of cancer. The use of eflornithine (DMFO) may be an effective way to prevent the
development of prostate cancer.
PURPOSE: Randomized phase II trial to determine the effectiveness of eflornithine in
preventing prostate cancer in patients who are at high risk of developing the disease.
Phase:
Phase 2
Details
Lead Sponsor:
Thomas E. Ahlering University of California, Irvine